Open AccessDisruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone
Author(s) -
Angela C. Hirbe,
Jessica B. Rubin,
Özge Uluçkan,
Elizabeth A. Morgan,
Mark C. Eagleton,
Julie L. Prior,
David PiwnicaWorms,
Katherine N. Weilbaecher
Publication year - 2007
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.0705203104
Subject(s) - osteoclast , bone resorption , homing (biology) , diphosphonates , zoledronic acid , chemistry , cxcr4 , haematopoiesis , resorption , bone metastasis , cancer research , endocrinology , medicine , in vitro , microbiology and biotechnology , biology , metastasis , biochemistry , receptor , stem cell , cancer , chemokine , ecology
CXCR4 regulates hematopoietic and tumor cell homing to bone, but its role during osteoclast (OC) development is unknown. We investigated the role of CXCR4 in osteoclastogenesis and in a model of bone metastasis. Compared with controls, mice reconstituted with CXCR4 null hematopoietic cells exhibited elevated markers of bone resorption, increased OC perimeter along bone, and increased bone loss. CXCR4−/− OCs demonstrated accelerated differentiation and enhanced bone resorptionin vitro . Furthermore, tumor growth specifically in bone was significantly increased in mice reconstituted with CXCR4−/− hematopoietic cells. Finally, enhancement of bone tumor growth in the absence of CXCR4 was abrogated with the OC inhibitor, zoledronic acid. These data demonstrate that disruption of CXCR4 enhances osteoclastogenesis and suggest that inhibition of CXCR4 may enhance established skeletal tumor burden by increasing OC activity.